These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36490316)

  • 1. SOBA: Development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers.
    Shea D; Colasurdo E; Smith A; Paschall C; Jayadev S; Keene CD; Galasko D; Ko A; Li G; Peskind E; Daggett V
    Proc Natl Acad Sci U S A; 2022 Dec; 119(50):e2213157119. PubMed ID: 36490316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-Sheet secondary structure in amyloid β-peptide drives aggregation and toxicity in Alzheimer's disease.
    Shea D; Hsu CC; Bi TM; Paranjapye N; Childers MC; Cochran J; Tomberlin CP; Wang L; Paris D; Zonderman J; Varani G; Link CD; Mullan M; Daggett V
    Proc Natl Acad Sci U S A; 2019 Apr; 116(18):8895-8900. PubMed ID: 31004062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of SOBA-AD blood test in discriminating Alzheimer's disease patients from cognitively unimpaired controls in two independent cohorts.
    Chen A; Shea D; Daggett V
    Sci Rep; 2024 Apr; 14(1):7946. PubMed ID: 38575622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
    Williams SM; Schulz P; Sierks MR
    Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Amyloid-β Component of Human α-Synuclein Oligomers Induces Formation of New Aβ Oligomers: Insight into the Mechanisms That Link Parkinson's and Alzheimer's Diseases.
    Atsmon-Raz Y; Miller Y
    ACS Chem Neurosci; 2016 Jan; 7(1):46-55. PubMed ID: 26479553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease.
    Santos AN; Ewers M; Minthon L; Simm A; Silber RE; Blennow K; Prvulovic D; Hansson O; Hampel H
    J Alzheimers Dis; 2012; 29(1):171-6. PubMed ID: 22214781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid.
    Savage MJ; Kalinina J; Wolfe A; Tugusheva K; Korn R; Cash-Mason T; Maxwell JW; Hatcher NG; Haugabook SJ; Wu G; Howell BJ; Renger JJ; Shughrue PJ; McCampbell A
    J Neurosci; 2014 Feb; 34(8):2884-97. PubMed ID: 24553930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease.
    Jongbloed W; Bruggink KA; Kester MI; Visser PJ; Scheltens P; Blankenstein MA; Verbeek MM; Teunissen CE; Veerhuis R
    J Alzheimers Dis; 2015; 45(1):35-43. PubMed ID: 25547634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.
    van Steenoven I; Aarsland D; Weintraub D; Londos E; Blanc F; van der Flier WM; Teunissen CE; Mollenhauer B; Fladby T; Kramberger MG; Bonanni L; Lemstra AW;
    J Alzheimers Dis; 2016 Aug; 54(1):287-95. PubMed ID: 27567832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
    Kaerst L; Kuhlmann A; Wedekind D; Stoeck K; Lange P; Zerr I
    J Alzheimers Dis; 2014; 38(1):63-73. PubMed ID: 23948928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refining the amyloid β peptide and oligomer fingerprint ambiguities in Alzheimer's disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma.
    Michno W; Blennow K; Zetterberg H; Brinkmalm G
    J Neurochem; 2021 Oct; 159(2):234-257. PubMed ID: 34245565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
    van Steenoven I; van der Flier WM; Scheltens P; Teunissen CE; Lemstra AW
    Alzheimers Res Ther; 2019 Oct; 11(1):83. PubMed ID: 31601267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α-synuclein-assisted oligomerization of β-amyloid (1-42).
    Chau E; Kim JR
    Arch Biochem Biophys; 2022 Mar; 717():109120. PubMed ID: 35041853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia.
    Bibl M; Mollenhauer B; Esselmann H; Lewczuk P; Klafki HW; Sparbier K; Smirnov A; Cepek L; Trenkwalder C; Rüther E; Kornhuber J; Otto M; Wiltfang J
    Brain; 2006 May; 129(Pt 5):1177-87. PubMed ID: 16600985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.
    Hey JA; Kocis P; Hort J; Abushakra S; Power A; Vyhnálek M; Yu JY; Tolar M
    CNS Drugs; 2018 Sep; 32(9):849-861. PubMed ID: 30076539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
    Izzo NJ; Yuede CM; LaBarbera KM; Limegrover CS; Rehak C; Yurko R; Waybright L; Look G; Rishton G; Safferstein H; Hamby ME; Williams C; Sadlek K; Edwards HM; Davis CS; Grundman M; Schneider LS; DeKosky ST; Chelsky D; Pike I; Henstridge C; Blennow K; Zetterberg H; LeVine H; Spires-Jones TL; Cirrito JR; Catalano SM
    Alzheimers Dement; 2021 Aug; 17(8):1365-1382. PubMed ID: 33559354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
    van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
    Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic insights into the role of amyloid-β in innate immunity.
    Prosswimmer T; Heng A; Daggett V
    Sci Rep; 2024 Mar; 14(1):5376. PubMed ID: 38438446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.